Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.
暂无分享，去创建一个
[1] Lucy F. Stead,et al. Glioma progression is shaped by genetic evolution and microenvironment interactions , 2022, Cell.
[2] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[3] R. Verhaak,et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in cancer patients , 2021, Nature Genetics.
[4] Raymond Y Huang,et al. Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.
[5] Jeffrey H. Chuang,et al. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS , 2019, Nature.
[6] C. Brennan,et al. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas , 2019, Clinical Cancer Research.
[7] Till Acker,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[8] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.